Is Microdosing Safe Long-Term? The Heart-Valve Risk

Over the short term, repeated low doses of LSD or psilocybin look fairly low-risk for most healthy people. The long-term answer is different. The main concern is heart-valve damage from cumulative activation of the 5-HT2B serotonin receptor, and there is almost no direct long-term human safety data to confirm it or rule it out. The concern is real at the mechanistic level. It has not been demonstrated in anyone who microdoses.

The receptor that ruined fen-phen

The 5-HT2B receptor sits on the cells of your heart valves. Activate it repeatedly and those cells multiply and lay down extra connective tissue. The leaflets thicken and stiffen and stop closing properly, blood leaks backward, and that is valvular regurgitation.

This is not a hypothetical pathway. It is the established cause of several drug disasters. Fenfluramine, the “fen-phen” diet combination, was pulled from the market in the 1990s after causing valve disease in thousands of users, and its metabolite is a potent 5-HT2B agonist. Pergolide and cabergoline, ergot-derived drugs for Parkinson’s and prolactin disorders, did the same at higher doses. So did methysergide, an older migraine drug. Bryan Roth’s commentary in the New England Journal of Medicine pulled those cases together and named 5-HT2B agonism as the shared mechanism behind all of them.

The pattern across every one of those drugs is consistent: it takes sustained, repeated exposure, not a single dose.

Where LSD and psilocin fit

In receptor-binding work, LSD and psilocin, the active form of psilocybin, are agonists at 5-HT2B. Rickli and Liechti measured functional activation at both 5-HT2A and 5-HT2B for LSD, psilocin and related tryptamines, confirming that these compounds engage 5-HT2B and not only the 5-HT2A receptor responsible for the psychedelic effect. LSD is also structurally an ergoline, the same chemical family as pergolide and methysergide, which is why anyone thought to ask the question in the first place.

The most direct analysis is a 2023 review by Tagen and colleagues, written specifically about valve-disease risk from chronic psychedelic and MDMA microdosing. LSD, psilocybin and DMT all came out as partial 5-HT2B agonists. The measured safety margins at typical microdose concentrations were wider than those of the known valve-damaging drugs, but the authors still landed on valve disease as a potential risk of chronic microdosing that further study is needed to define. Rouaud and colleagues, reviewing the field in 2024, noted the same structural similarity to fenfluramine and pergolide and said plainly that the long-term cardiac effects of microdosing remain unknown.

What is actually known, and what is not

We have strong receptor pharmacology showing LSD and psilocin activate 5-HT2B. We have a decades-deep, high-confidence link between 5-HT2B agonism and valve disease in other drugs. And we have two peer-reviewed reviews raising the question for microdosing specifically.

We do not have a single long-term study following microdosers’ heart valves on echocardiography. We do not have one reported clinical case of microdosing-induced valvulopathy. And there is no agreed threshold for how much cumulative dose, at what frequency, would be needed to cause harm, if any amount is.

So this concern sits in the mechanistic and extrapolated tier of evidence, not the clinical-outcome tier. Plausible enough that serious researchers publish on it, unproven enough that nobody can quote you a real-world risk number. Both are true at once. And the absence of case reports is not evidence of safety. It is what you would expect from a question nobody has gone looking for.

It also matters why people microdose at all. The strongest controlled trial to date found the reported benefits were largely explained by expectation, with little separation from placebo. We go through that in our evidence review of microdosing psilocybin. A small measurable upside against a genuinely unknown long-term risk is a different calculation than the one most people think they are making.

One trip is not the same as a hundred small ones

A single full-dose experience is one large but brief exposure. Microdosing is many small exposures stacked over months or years, and cumulative 5-HT2B exposure is exactly what drove valve disease with fenfluramine and pergolide. For this particular risk, frequency and duration are the variables that matter, not peak intensity.

Which means a few full-dose experiences spread across a year is a different pharmacological question than dosing two to four times a week for several years. The valve concern is squarely about the second pattern.

If you are going to do it anyway

Keep the dose genuinely sub-perceptual. If you can feel it, it is too high, and a higher dose means more cumulative 5-HT2B load for none of what you were after.

Run time-limited courses rather than open-ended ones. Several weeks on, then a break of months, holds cumulative exposure far below continuous daily use. Years of uninterrupted dosing is the pattern that mattered for the other 5-HT2B drugs.

If you dose regularly, get your heart looked at, particularly if you have ever had a murmur or a valve problem, or took fenfluramine, dexfenfluramine, or an ergot-derived drug in the past. Existing valvular heart disease is the one clear reason not to microdose at all. If you take other serotonergic medication there are separate interaction concerns, and our LSD guide covers the lithium and SSRI cautions.

None of this makes microdosing proven dangerous. It means the long-term question is open, the most evidence-grounded concern is your heart valves, and the people with the most to lose are the ones who already have valve disease. If you are still deciding whether to start, our psilocybin guide has the honest version of the benefits.

Sources

Roth NEJM commentary on 5-HT2B agonism and valvulopathy PMID 17202450 | Rickli and Liechti receptor pharmacology PMID 27216487 | Tagen 2023 microdosing valve-risk review PMID 37572027 | Rouaud 2024 review PMID 38214279